

LakePharma
The Biologics Company

Marketing and Design Intern

Jun 2019 - Jun 2021

LakePharma, a B2B pharmaceutical company.

Goal: Promote and educate potential clients on LakePharma's hybridoma services with a new website brand for hybridoma.com.

Responsibilities:
PM, Design, Developer

- Managed project timeline and priorities using a gantt chart
- Created designs, illustrations, and graphics using Adobe Illustrator and Photoshop, and homepage animation using Adobe Premiere and After Effects
- Solo developer of hybridoma.com, using Wordpress, HTML, and CSS for desktop and mobile



HYBRIDOMA.COM
Powered by LakePharma

History Biology Technology Discovery About

ENABLING ANTIBODY DISCOVERY

HYBRIDOMA.COM
Powered by LakePharma

History Biology Technology Discovery About

Timeline

Learn more about the evolution of hybridoma technologies

View Timeline

HYBRIDOMA.COM
Powered by LakePharma

History Biology Technology Discovery About

Antibody Structure

Along with the double helix of DNA, the distinctive Y-shape of an antibody is one of the most recognized structures in biology and perhaps all of science. There are five classes of antibodies in humans and rodents defined by their respective immunoglobulin (Ig) heavy chains: IgG, IgM, IgD, IgA, and IgE. Here we focus on IgG, as it is one of the most abundant proteins in human serum (10-20% of total plasma protein), comprises 70-85% of the total immunoglobulin pool, has the longest plasma half-life (20-24 days), and it is the most common format used in antibody-based therapeutics. IgG (~150 kD) comprises four peptide chains: two identical heavy chains and two identical light chains connected by disulfide (S-S) bonds. The heavy chain in IgG comprise ~450 residues. There are four IgG subclasses in human (IgG1, IgG2, IgG3, and IgG4), five in mice (IgG1, IgG2a, IgG2b, IgG2c, IgG3), and four in rats (IgG1, IgG2a, IgG2b, IgG2c). The light chain in IgG comprise ~215 residues, and there are two light chain subclasses in humans, mice, and rat:

HYBRIDOMA.COM
Powered by LakePharma

History Biology Technology Discovery About

About Hybridoma.com

Hybridoma.com is developed by the scientists at LakePharma who are very passionate about discovering high performance antibodies using the hybridoma approach. Its goal is to serve as a reference source for researchers who are interested to learn more about hybridoma-based antibody discovery. If you have any questions, constructive feedback, corrections, or suggestions on improving this website, please do not hesitate to contact us.

Policy Statement

LakePharma reserves the copyright over the materials produced. The use of information and images on this website is encouraged, but proper citation of this website is required.

HYBRIDOMA.COM
Powered by LakePharma

History Biology Technology Discovery About

Success

01
The Discovery Immunology (DI) business unit has served 45 Companies so far.

02
38% of our clients have returned to pursue additional DI Ab campaigns. 36% of our clients perform multiple campaigns in parallel.

03
We have completed 97 discovery campaigns through the hit identification stage.

04
We have successfully identified, confirmed, and cryopreserved multiple hits (non-clonal hybridomas) for 97% of our campaigns.

05
We have successfully single-cell cloned multiple hybridomas and determined unique mAb sequences for 55+ campaigns.

HYBRIDOMA.COM
Powered by LakePharma

History Biology Technology Discovery About

Questions, comments, or looking to partner?

Contact Us

Email*

First name*

Last name*

Company name*

Message

Graphics

Infographics



Email Signatures



Flyer Layouts





Icons